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Abstract
Background: Src, a non-receptor tyrosine kinase is elevated in cancer with expression and activity correlated with cell
proliferation, adhesion, survival, motility, metastasis and angiogenesis. There is limited data on Src expression and
subcellular localization in breast cancer and no information about expression in racial/ethnic groups.
Methodology/Principal Findings: The present study evaluated Src expression, activity, and subcellular localization in triple
negative breast cancer (TNBC) and ERa positive breast cancer (ER+BC), cancer tissue and adjacent normal epithelial ducts,
and Caucasian and African American cases. 79 paraffin embedded breast carcinoma cases were obtained from Tulane
University Hospital between 2007–2009. 39 cases represented TNBC (33-African Americans, 4-Caucasians, 2-unknowns) and
40 cases represented ER+BC (21-African Americans, 16-Caucasians, 3-unknowns). Immunohistochemistry was used to
measure staining distribution and intensity of total Src and activated phospho-SrcY416 (p-Y416Src) in carcinoma tissue and
adjacent normal mammary ducts. In TNBC and ER+BC, total Src was significantly higher in cancer compared to adjacent
normal ducts (P,0.0001) in both cell membrane and cytoplasm. In membranes, p-Y416Src was elevated in cancer compared
to normal ducts. Total Src in the tumor cytoplasm was significantly higher in TNBC compared to ER+BC (P=0.0028);
conversely, p-Y416Src in the tumor cell membranes was higher in TNBC compared to ER+BC (P=0.0106). Comparison
between African American (n=21) and Caucasian ER+BC (n=16) revealed no significant difference in expression and
localization of total Src and p-Y416Src. TNBC cases positive for lymph node metastasis showed elevated membrane p-
Y416Src compared to lymph node negative TNBC (P=0.027).
Conclusion/Significance: Total Src and p-Y416Src were expressed higher in cancer compared to adjacent normal ducts.
Cytoplasmic total Src and membrane p-Y416Src were significantly higher in TNBC compared to ER+BC. TNBC cases with
lymph node metastasis showed elevated membrane p-Y416Src. Taken together, Src was elevated in the membrane and
cytoplasm of more aggressive TNBC.
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Introduction
Triple negative breast cancer (TNBC) are tumors that lack
expression of estrogen receptor a (ERa), progesterone receptor
(PR), and amplification/overexpression of human epidermal
growth factor receptor 2 (HER2/neu). TNBC comprises 15% of
all breast cancers and occurs with greater frequency in younger
patients and in African American women [1,2]. TNBC exhibits a
more aggressive phenotype and patients have poor prognosis and
shorter time to recurrence compared to ERa positive breast cancer
(ER+BC) [3,4]. Only 30% of women with metastatic TNBC
survive 5 years, and many patients eventually die of their disease
[4]. Patients with TNBC have been difficult to treat due to
heterogeneity within the tumors and lack of definitive targets for
development of targeted therapeutics [5,6]. This lack of effective
targeted therapies for TNBC, the disproportionate incidence of
TNBC in African American women, and the earlier age of onset
highlights an urgent need for novel therapeutic strategies for
TNBC [7].
c-Src is an oncogenic non-receptor tyrosine kinase that is up-
regulated in approximately half of all breast cancers [8,9,10]. A
number of studies have demonstrated an elevation in the level and/or
activity of Src kinase during progression of breast cancer and
numerous reports and commentary highlight the value of targeting
Src in breast cancer [11,12,13]. Subcellular localization of Src is a key
regulatory mechanism for control of Src activation. Src remains
inactive in the cytoplasm when it is phosphorylated at Y530; once
dephosphorylated, Src translocates to the cell membrane and becomes
fully activated by autophosphorylation at Y416 [14,15,16,17]. The
activated Src (p-Y416Src) at the cell membrane initiates intracellular
signal transduction pathways that influence cell proliferation and
adhesion that contributes to cell growth and migration [18].
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and migration/invasion [19,20,21]. The role of Src in prolifera-
tion, migration and invasion coupled with the elevated Src
expression in breast cancer combine to make inhibition of Src a
promising target for development of therapeutics. Most impor-
tantly, inhibition of Src has recently been identified as a
therapeutic target for basal breast cancers including the TNBC
subtype [22,23]. It will be critical to identify breast cancer patients
who may benefit from therapy directed at inhibition of Src kinase.
There are few published studies on the expression of Src kinase
in clinical breast cancer [24,25,26,27]. No studies have compared
TNBC and ER+BC for subcellular localization of Src, Src
expression in tumor versus normal cells, or racial/ethnic
differences in Src expression. Elevated Src expression and activity,
and subcellular localization of Src to the membrane may identify a
subset of breast cancer patients who will respond favorably to Src
targeted therapy. The present study was undertaken to systemat-
ically compare expression, activity and subcellular localization of
Src in TNBC and ERa positive breast cancers.
Results
Src expression in breast cancer tissue and adjacent
normal ducts in ER+BC and TNBC
Table 1 summarizes the clinical-pathological features of the
breast cancer cases used in this study. Src expression in cancer cells
and in adjacent normal epithelial ducts was scored and compared in
tissue sections from resected tumors of BC patient seen in the
Tulane University Hospital and Clinics, New Orleans, LA. Sections
werestainedwith an antibodydirected against totalSrcprotein,and
withanantibodythatinteractedwithSrcphosphorylatedattyrosine
(Y) 416 which represents the active form of Src kinase. In ER+BC
cases, statistical analysis revealed that total Src expression was
significantly higher in cancer tissue when compared to adjacent
normal epithelial ducts in both the cell membrane (P,0.0001) and
the cell cytoplasm (P,0.0001) (Fig. 1A). Phospho-Src (p-Y416Src)
was more intensely stained in the cell membrane of cancerous tissue
compared to normal ducts (P=0.0076), whereas there was no
difference in the expression of p-Y416Src between cytoplasm of
normal ducts and cancer tissue (P=0.2227) (Fig. 1B). Src was not
detected in the cell nucleus for any of the ER+BC or TNBC cases.
Similar to ER+BC, in TNBC cases total Src expression was
significantly higher in cancer tissue when compared to adjacent
normal ducts in both the cytoplasm (P=0.0016) and the
membrane (P,0.0001) (Fig. 1C). Strong membrane p-Y416Src
staining was observed in cancer compared to normal ducts
(P=0.0014); however similar to ER+BC, there was no difference
in levels of cytoplasmic p-Y416Src between normal ducts and
cancer (P=0.2502) (Fig. 1D). Figure 1E, F shows representative
total Src in the cell cytoplasm and cell membrane respectively of
the adjacent normal ducts of TNBC. Figure 1G, H shows
representative p-Y416Src in the cytoplasm and membrane
respectively of the adjacent normal ducts of TNBC.
Total Src expression and subcellular localization in cancer
cells
95% (37/39) of TNBC cases demonstrated positive total-Src
staining in the cytoplasm and 79% (31/39) of TNBC cases
demonstrated positive total-Src staining in the membrane
(Table 2). 90% (36/40) of ER+BC cases showed cytoplasmic
staining for total-Src and 70% (28/40) of ER+BC cases showed
membrane staining for total Src (Table 2).
p-Y416Src expression and subcellular localization in
cancer cells
79% (31/39) of TNBC cases stained positive for cytoplasmic p-
Y416Src and 68% (27/40) of ER+BC cases showed positive staining
Table 1. Patient and tumor characteristics.
Patient and tumor characteristics Variables TNBC (n=39) ER+ BC (n=40)
Patient age #50 19 11
.50 20 29
Race African American 33 21
Caucasian 4 16
Others 2 3
Grade Grade 1 1 9
Grade 2 7 19
Grade 3 28 7
Histological type Invasive ductal carcinoma 33 29
Invasive lobular carcinoma 0 4
DCIS 3 5
Others 3 2
Lymph node status Negative 10 8
Positive 13 8
Not tested 16 24
Ki67 status Low (#20%) 4 25
High (.20%) 31 13
Unknown 4 2
Clinical-pathological characteristics of TNBC and ER+BC cases.
n- number of cases.
doi:10.1371/journal.pone.0033017.t001
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33017Figure 1. Src expression in breast cancer tissue and adjacent normal ducts of ER+BC and TNBC. A) Comparison between total Src (t-Src)
subcellular localization in cytoplasm (Cyto) and membrane (Mem) of normal ducts and cancer of ER+BC; B) Comparison between p-Y416Src (p-Src)
expression in cytoplasm and membrane of normal ducts and cancer of ER+BC; C) Comparison between total Src expression in cytoplasm and
membrane of normal ducts and cancer of TNBC; D) Comparison between p-Src expression in cytoplasm and membrane of normal ducts and cancer in
TNBC. Statistical difference in the distribution of total and p-Y416Src kinase in normal ducts and cancer was analyzed by the Mann-Whitney U test,
*P ,0.05, **P,0.01, *** P,0.001. All error bars represent the SEM (standard error of mean). E) A representative photomicrograph from a TNBC case
showing a weak cytoplasmic (1+) t-Src staining in normal ducts as indicated by a black arrow. F) A representative photomicrograph from a TNBC case
showing a weak membrane (1+) t-Src staining in normal ducts as indicated by a red arrow (original magnification 6200). G) A representative
photomicrograph from a TNBC case showing a weak cytoplasmic p-Src staining (1+) in normal ducts as indicated by a black arrow. F) A representative
Src Kinase in Breast Cancer
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membrane p-Y416Src in 67% (26/39) cases whereas only 40% of
the ER+BC cases showed membrane p-Y416Src staining (Table 2).
The Chi-square test revealed that membrane p-Y416Src was
detected more frequently in TNBC cases (67%, 26/39) than in
ER+BC (40%, 16/40) (P=0.0176) (Table 2).
Src and p-Y416Src expression and subcellular localization
in ER+BC among African Americans and Caucasians cases
There was no significant difference in the expression or localization
of either total Src or p-Y416Src in ER+BC between African American
(n=21) and Caucasian (n=16) cases (Fig. 2A). The comparison of Src
expression in TNBC between African American (n=33) and
Caucasian cases (n=4) was not done due to insufficient Caucasian
sample size available from Tulane University Hospital and Clinics.
Src expression and subcellular localization among African
American TNBC and ER+BC
No significant difference was detected in total Src and p-
Y416Src expression and subcellular localization between African
American TNBC (n=33) and African American ER+BC (n=21)
cases (Fig. 2B), although African American TNBC exhibited a
trend towards an increase in the expression of cytoplasmic total
Src (P=0.060) and membrane p-Y416Src (P=0.095) as compared
to African American ER+BC.
Src and p-Y416Src expression and subcellular localization
in TNBC and ER+BC regardless of race
The comparison of TNBC (n=39) and ER+BC (n=40) cases
regardless of race revealed that total Src expression in the cytoplasm
was significantly higher in TNBC compared to ER+BC (P=0.0028)
(Fig. 3A–C). No significant difference was observed in total Src
expression in the membrane for TNBC versus ER+BC (P=0.2083)
(Fig. 3A, D, E). Conversely, p-Y416Src expression in the membrane
was significantly higher (P=0.0106) in TNBC when compared to
ER+BC (Fig. 4A–C). No difference was observed in cytoplasmic p-
Y416Src between TNBC or ER+BC cases (P=0.5415) (Fig. 4A, D, E).
Impact of age, tumor grade, proliferation status and
lymph node metastasis on Src kinase expression and
subcellular localization
TNBC cases that were positive for lymph node metastasis
(n=13) exhibited higher membrane p-Y416Src compared to
lymph node negative TNBC cases (n=10) (P=0.027) (Table 3),
whereas cytoplasmic p-Y416Src expression in lymph node positive
TNBC cases and lymph node negative TNBC cases were not
significantly different (P=0.656) (Table 3). In ER+BC, there was
no statistically significant difference in subcellular localization of
total Src or p-Y416Src expression between lymph node positive
and lymph node negative cases (Table 4). Moreover, total Src and
p-Y416Src expression in both ER+BC and TNBC did not exhibit
significant differences in subcellular localization when comparing
age (women of age#50 and women of age .50) (Table S1A, B),
tumor grade (1, 2 and 3) (Table S2A, B), or proliferation status
(high and low Ki67 index) (Table S3A, B). These data indicated
that elevated membrane p-Y416Src was detected in TNBC cases
with lymph node metastasis, but Src expression/activity and
subcellular localization was not associated with age, tumor
proliferation or tumor grade in either TNBC or ER+BC in this
data set.
Discussion
Although a number of studies have examined Src kinase
expression in breast cancer [24,25,26,27], to our knowledge, no
studies have combined investigation of Src expression, activity and
localization in comparing TNBC with ER+BC, cancer tissue with
normal epithelial ducts, and Caucasian with African American
ethnic groups. In addition to measuring total Src expression, it is
important to measure the level of active Src [27] and evaluate
membrane localization, since these latter two assessments may be
more appropriate biomarkers for predicting clinical response to
Src kinase inhibitors. Currently, p-Y416Src is most commonly
assessed to determine the level of active Src. The present single site
study using samples from breast cancer patients seen at the Tulane
University Hospital and Clinics, New Orleans, Louisiana, found
that both cytoplasmic and membrane Src were detected in the
majority of breast cancer cases. The systematic examination of
expression, activity and subcellular localization of Src in TNBC
and ER+BC demonstrated that total Src expression was higher in
cancer when compared to adjacent normal ducts in both the cell
membrane and the cytoplasm. Active p-Y416Src was elevated in
the membranes of cancer cells compared to normal ducts. Total
Src in the cytoplasm and p-Y416Src in the membrane was
elevated in TNBC compared to ER+BC. No difference in the
expression and activity of Src at any cellular location was found
when age (#50 versus.50), high/low ki67 index, or tumor grade
(1, 2 and 3) was compared. TNBC cases with positive lymph
node metastasis showed elevated p-Y416Src in the membranes of
cancer cells compared to TNBC cases that were negative for
lymph node metastasis. These data demonstrate that elevated Src
expression correlated with more aggressive TNBC, although no
racial/ethnic differences in Src were observed within the limited
data set of ER+BC.
Subcellular localization of Src is a key regulatory mechanism for
control of Src activation. Upon external stimuli, inactive Src in the
cytoplasm is translocated to the cell membrane and activated by
phosphorylation [14,15,16,17]. The p-Y416Src at the cell
membrane has been shown to initiate intracellular signal
transduction pathways that influence cell adhesion and initiate
cell migration [18]. A study by Reissig et. al. that found elevated
Src expression and activity in cancer tissue when compared with
adjacent matched normal tissue in 25 of 52 breast cancer cases but
photomicrograph from a TNBC case showing a weak membrane (1+) p-Src staining in normal ducts as indicated by a red arrow (original magnification
6200) Scale bar, 50 mm. Insets are magnified images from selected areas (small squares) to show the membrane and cytoplasmic Src staining clearly.
doi:10.1371/journal.pone.0033017.g001
Table 2. Subcellular localization of total Src and p-Y416Src in
TNBC and ER+BC cases.
Variable TNBC (n=39) ER+ BC (n=40) P value
Cytoplasmic total Src 95% (37/39) 90% (36/40) 0.413
Membrane total Src 79% (31/39) 70% (28/40) 0.332
Cytoplasmic p-Y416Src 79% (31/39) 68% (27/40) 0.227
Membrane p-Y416Src 67% (26/39) 40% (16/40) 0.017*
The Chi-square test was used to analyze the frequency of Src distribution and
determine differences between TNBC and ER+BC cases.
*P,0.05 was considered to be a statistically significant difference in the
distribution of Src between TNBC and ER+BC cases.
doi:10.1371/journal.pone.0033017.t002
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[25]. The present study provides additional details regarding the
subcellular localization of total and active Src. We report that p-
Y416Src expression in the membrane was significantly higher in
TNBC compared to ER+BC. A previous study by Tryfonopoulos
et al. reported an increase of total Src in membrane of TNBC
compared to non-TNBC cases, but did not address active Src [28].
In addition to elevated active Src in the membrane of TNBC cells,
there was a higher level of total Src in the cytoplasm of TNBC
compared to ER+BC. Studies have shown that breast cancer
patients with elevated total Src in the cytoplasm had a lower
disease specific survival compared to patients with low cytoplasmic
Src [29]. Several studies have demonstrated that TNBC has a
poor survival outcome compared to ER+BC [3,4]. The elevated
detection of p-Y416Src in the membrane of TNBC coupled with
elevated total Src in the cytoplasm of TNBC is consistent with the
more aggressive and metastatic phenotype of TNBC compared to
other breast cancer subtypes [22].
In the present study neither TNBC nor ER+BC showed any
significant differences in expression, activity or subcellular loca-
lization of Src when comparing age, tumor grade or Ki67 status. A
higher level of p-Y416Src (active form) was detected in the
membrane of cancer cells from TNBC patients that had lymph
node positive disease as compared to patients classified as lymph
node negative. This is consistent with the known role of c-Src in
cancer cell invasion and metastasis. In addition, p-Y416Src was
localized to the membrane more frequently in more aggressive
TNBC specimens as compared to the less aggressive ER+BC
specimens. These data suggested that membrane localized active
Src may be correlated with aggressive and/or metastatic disease
and are consistent with previous studies comparing Src expression
in other breast cancer subtypes. A recent study demonstrated that
high expression of p-Y416Src was associated with breast cancer
metastatic disease although cytoplasmic/membrane localization of
activated p-Y416Src was not assessed [30]. Other studies have
shown that cancer cell lines with elevated Src activity are
frequently highly metastatic, exhibiting an elevated migration
and invasion potential in vitro [31,32,33]. Taken together, the
present study found that p-Y416Src (active form) was localized to
the membrane more frequently in aggressive TNBC as compared
to less aggressive ER+BC.
With the understanding that Src may promote breast cancer
invasiveness, it might be expected that clinical Src inhibitors could
be effective in inhibiting metastatic breast cancer. However to
Figure 2. Src expression in African American and Caucasian breast cancer. A) Comparison of total Src (t-src) subcellular localization in the
cytoplasm (Cyto) and membrane (Mem) among African American (AA) and Caucasian (Cau) ER+BC cases. B) Comparisons of p-Y416Src (p-Src)
localization (cytoplasmic/membrane) among African American (AA) and Caucasians in ER+BC. C) Comparison of total Src subcellular localization
(cytoplasmic/membrane) among TNBC and ER+BC in African Americans. D) Comparisons of p-Src subcellular localization (cytoplasmic/membrane)
among TNBC and ER+BC in African Americans. Statistical differences in the distribution of total and p-Src kinase were analyzed by the Mann-Whitney
U test. ns - not significant. The graphs represent the mean histoscore 6 SEM (standard error of mean).
doi:10.1371/journal.pone.0033017.g002
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breast cancer patient groups have been very modest [34,35,36]. A
phase II clinical trial using the broad specificity Src kinase
inhibitor dasatinib as a single agent in patients with metastatic
TNBC showed only a modest response rate of 5% [34,35]. A
phase II trial using another broad specificity Src inhibitor
saracatinib in hormone receptor negative breast cancer patients
(n=9) did not provide positive results; no patient achieved
complete response (CR), partial response (PR), or stable disease
(SD) at .6 months [36]. It is unknown why these clinical Src
inhibitors did not result in a more significant response rate. It is
noted that Src expression in tissue biopsies from patients in these
studies was not assessed. The Src inhibitors used in these studies
represent the ATP analogue class of inhibitors that bind in the
ATP-binding pocket of Src and many other tyrosine kinases and
hence do not exhibit complete specificity for Src kinase. It is
unknown whether the broad specificity of current ATP analogue
Src inhibitors may underlie problems with efficacy in breast cancer
patients. These studies indicate a need for stratification of patients
to identify those who are likely to respond to a Src inhibitor. More
understanding about the level and activity of Src related to
subcellular localization, race/ethnicity, and relationship to breast
tumor subtypes may permit clinicians to better predict patients
who will respond to Src kinase inhibitors.
Figure 3. Evaluation of total Src expression in TNBC and ER+BC. A) Comparison of subcellular localization in the cytoplasm (Cyto) and
membrane (Mem) of total Src (t-src) in TNBC and ER+BC. B) Representative TNBC case showing strong cytoplasmic (3+) t-Src staining (shown by
arrows) (original magnification 6200). C) Representative ER+BC case showing moderate cytoplasmic (2+) t-Src staining (shown by arrows) (original
magnification6200). D) Representative TNBC case showing strong membrane (3+) t-Src staining (shown by arrows) (original magnification6200). E)
Representative ER+BC case showing moderate membrane (2+) t-Src staining (shown by arrows) (original magnification6200). Statistical differences in
the distribution of t-Src in TNBC and ER+BC was analyzed by the Mann-Whitney U test, **P,0.01, ns - not significant. Scale bar, 50 mm. Insets are
magnified images from selected areas (small squares) to show the membrane and cytoplasmic Src staining clearly.
doi:10.1371/journal.pone.0033017.g003
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33017Figure 4. Evaluation of active Src expression in TNBC and ER+BC. A) Comparison between subcellular localization in the cytoplasm (Cyto)
and membrane (Mem) of p-Y416Src (p-Src) in TNBC and ER+BC. B) Representative TNBC case showing strong membrane (3+) p-Src staining (shown by
arrows) (original magnification 6200). C) Representative ER+BC case showing moderate membrane (2+) p-Src staining (shown by arrows) (original
magnification 6200). D) Representative TNBC case showing moderate cytoplasmic (2+) p-Src staining (shown by arrows) (original magnification
6200). E) Representative ER+BC case showing moderate cytoplasmic (2+) staining of p-Src (shown by arrows) (original magnification6200). Statistical
differences in the distribution of p-Src in TNBC and ER+BC was analyzed by the Mann-Whitney U test, * P,0.05. ns - not significant. Scale bar, 50 mm.
Insets are magnified images from selected areas (small squares) to show the membrane and cytoplasmic Src staining clearly.
doi:10.1371/journal.pone.0033017.g004
Table 3. Relationship between lymph node status and Src expression/activity/localization in TNBC.
Variable Lymph node positive (n=13) Lymph node negative (n=10) P value
Cytoplasmic total Src 5.7460.56 5.1460.29 0.143
Membrane total Src 4.5460.64 3.0360.82 0.110
Cytoplasmic p-Y416Src 2.4960.51 2.2360.80 0.656
Membrane p-Y416Src 3.2360.66 0.7660.58 0.027*
Mean histoscore values 6 SEM (standard error of mean) were calculated for total Src and p-Y416Src expression in lymph node positive and negative cases of TNBC.
Statistical differences in the distribution of Src and p-Y416Src in TNBC were calculated using the Mann-Whitney U test.
*P,0.05 was considered statistically significant.
doi:10.1371/journal.pone.0033017.t003
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restricted to any pathological subtype. Three TNBC cases were
DCIS and five ER+BC cases were DCIS. These DCIS cases were
useful in evaluating Src expression in the progression from normal
breast epithelium, to DCIS and invasive disease. Recently, Humar
et. al. detected increased levels of active Src (p-Y416Src) in
invasive lobular carcinoma (LBC) relative to non-invasive lobular
carcinoma in situ (LCIS) or non-neoplastic epithelia in LBC
patients [37] suggesting that the acquisition of invasiveness
coincides with increased active Src in the membrane. In the
present study only four LBC cases were identified that were also
TNBC; active Src was not detected in the membrane of these
tumors although no conclusions can be made due to low sample
number. The majority of the cases in the present study were
invasive ductal carcinoma that showed elevated levels of Src and
active Src (p-Y416Src) in cancer cell membrane relative to
adjacent normal ducts. Of the eight cases that had regions of
ductal carcinoma in situ (DCIS), five of these DCIS cases showed
increased active Src in the membrane of the DCIS regions. The
present data evaluating ductal carcinomas are consistent with the
data on lobular carcinoma in which Src and active Src are
increased with the progression from benign, to in situ, to invasive
disease. Src protein expression was not detected in the cell nucleus
in the present study or in two other previous studies [28,30].
However, Elsberger et. al. detected total Src nuclear staining in
48% and p-SrcY416 in 92% of breast cancer cases [27]. Another
study by the same group detected active Src within the nucleus of
tumor cells in over 50% of breast cancer cases that was
significantly associated with improved patient survival and
decreased recurrence in tamoxifen-treated patients with ER+BC
[26]. A limitation of the present study was lack of long-term follow
up data for the breast cancer cases. All cases were from recent
years (2007–2009) and long-term follow-up on recurrence and
data to calculate survival curves were not available. Older archival
specimens were not available from the tumor bank because of
sustained flooding that occurred in late 2005 from Hurricane
Katrina.
In ER+BC, a comparison between African American and
Caucasian cases revealed no significant differences in the
expression, activity and localization of Src between these ethnic
groups. Breast cancer patients seen in the Tulane University
Hospital and Clinics are predominantly African American women
who present with TNBC with few Caucasian women who present
with TNBC. The number of available cases of Caucasian women
who presented with TNBC (n=4) 2007–2009 was not a sufficient
sample size to make conclusions about racial/ethnic differences in
Src expression in TNBC. Within all the African American breast
cancer cases, total and active Src was elevated in TNBC compared
to ER+BC.
Materials and Methods
Ethics statement
The specimens to be used in this research project were obtained
under IRB protocol #10-169449 approved by the Tulane
University Institutional Review Board (IRB). No patient identifiers
were associated with the samples used in this study. This study
used archival biopsies of breast cancer and there was no
recruitment of patients. Specimens were used from women who
have previously consented to donate biological specimens to the
Tulane Hospital specimen repository.
Tissue cases
A total of 79 paraffin tissue samples were obtained from patients
who were diagnosed with breast cancer at Tulane University
Hospital and Clinics between 2007 and 2009. All the breast cancer
cases were procured from the Department of Pathology, Tulane
Health Sciences Center with IRB approval. Since all breast cancer
cases were from recent years, long-term follow-up data to calculate
survival curves was not available. In the present study all tumor
samples or biopsies from breast cancer patients were collected and
transferred to 10% neutral buffered formalin within 15 minutes of
excision to minimize loss of phospho-antigens. Race, age, tumor
type, size, grade, Ki67 status, lymph node status, and ERa/PR/
HER2/neu expression were obtained from the pathology case
reports. Thirty-nine (39) cases represented TNBC (33 African
Americans, 4 Caucasians, 2 race unknowns) and 40 cases
represented ER+BC (21 African Americans and 16 Caucasians,
3 race unknowns).
TNBC cases. All TNBC cases were negative for ERa/PR
expression, and Her2/neu amplification/overexpression. Tumor
type: 33 cases were invasive ductal carcinoma, 3 cases were ductal
carcinoma in situ (DCIS), 1 case was adenoid cystic carcinoma, 1
case anaplastic giant cell carcinoma and 1 case was mucinous
carcinoma. Tumor grade: 1 case was grade 1, 7 cases were grade
2, 28 cases were grade 3. Ki67 expression: 31 cases had a high
Ki67 index (.20% Ki67 staining), 4 cases had a low Ki67 index
(#20% staining), 4 unknown. Lymph node status: 13 cases were
lymph node positive and 10 cases were lymph node negative; for
the remaining 24 cases lymph node status was not checked. Age:
Of 39 TNBC cases, 20 cases were over 50 years of age, 19 cases
were under 50 years of age.
ER+BC cases. All cases were PR positive and ERa status was
90% positive or greater. 16 cases had PR status of 90% and 24
cases had less than 90% PR staining. Tumor type: 29 cases were
invasive ductal carcinoma, 4 cases were invasive lobular
carcinoma, 5 cases were DCIS, 1 case was papillary carcinoma,
and 1 case was mucinous adenocarcinoma. Tumor grade: 9 cases
were grade 1, 19 cases were grade 2, and 7 cases were grade 3.
Table 4. Relationship between lymph node status and Src expression/activity/localization in ER+BC.
Variable Lymph node positive (n=8) Lymph node negative (n=8) P value
Cytoplasmic total Src 4.6660.37 2.6060.91 0.220
Membrane total Src 2.8860.72 1.8960.90 0.410
Cytoplasmic p-Y416Src 1.6060.47 1.6760.86 0.822
Membrane p-Y416Src 1.1260.71 1.0860.73 0.945
Mean histoscore values 6 SEM (standard error of mean) were calculated for total Src and p-Y416Src expression in lymph node positive and negative cases of ER+BC.
Statistical differences in the distribution of Src and p-Y416Src in ER+BC were calculated using the Mann-Whitney U test. *P,0.05 was considered statistically significant.
doi:10.1371/journal.pone.0033017.t004
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cases had a high Ki67 index (.20% Ki67 staining), and 2 cases
were unknown. Lymph node status: 8 cases were lymph node
positive and 8 cases were lymph node negative, for the remaining
24 cases lymph node status was not determined. Age: Of 40
ER+BC cases, 29 cases were over 50 years of age, 11 cases were
under 50 years of age.
Immunohistochemistry
Total Src kinase and activated phospho Src kinase expression
(p-Y416Src) was assessed by IHC using antibodies against total c-
Src (36D10; CAT # 2109, Cell Signaling Technology, Beverly,
MA) and p-Y416Src (CAT # 2101, Cell Signaling Technology,
Beverly, MA). These antibodies have been used in several studies
that measured Src expression and activity by IHC [30,38].
Immunohistochemistry (IHC) was performed as previously
described in our laboratory [39]. Briefly after deparaffinization
and rehydration of sections, antigen retrieval was performed by
immersing slides in Borg Decloaker (antigen retrieval solution)
(Biocare Medical, Concord, CA) and heating in a steam cooker for
20 minutes followed by cooling for 20 minutes at room temper-
ature. Endogenous peroxidase activity in tissue sections was
inhibited by incubation in 3% hydrogen peroxide (H2O2) for
5 minutes. To reduce nonspecific binding, tissue sections were
subsequently incubated with background sniper (Biocare Medical,
Concord, CA) for 5 minutes at room temperature. Slides were
then incubated overnight at 4uC with antibody to c-Src (1:200
dilution in PBS) or phospho-Y419Src (1:100 dilution in PBS).
Signal was amplified and visualized using MACH 4 Universal
HRP Polymer Detection (Biocare Medical, Concord, CA) and the
chromogen 3, 39-diaminobenzidine (DAB) (Vector Laboratories
Burlingame, CA). Sections were counterstained with hematoxylin,
dehydrated, and mounted. To evaluate the specificity of
immunostaining, the primary Src antibody or phospho-Y419Src
antibody was replaced with non-specific, isotyped matched rabbit
IgG diluted in PBS. Specificity of all antibodies was confirmed by
Western blotting.
Scoring
Src expression in tumor cases was measured by IHC and
assessed using the histoscore method developed by Allred et al.
[41]. Staining for Src in each cellular location (cytoplasm and
membranes) was scored separately for each sample. For each
specimen, a proportion score and an intensity score were
determined. The intensity of immunostaining was scored based
on a visual assessment of the staining intensity (brown color) within
the cytoplasm or cell membrane on a scale of 0 (no staining) to 3+
(intense staining). The intensity score represented the staining
intensity in positively stained cells (0=none; 1=+ weak; 2=++
intermediate, 3=+++ strong). The proportion score represented
the percentage of positively stained cells by microscopic examina-
tion of the entire tissue section (0=none; 1=,5%; 2=5–25%;
3=26–50% 4=51–75% 5=.75%) [40]. For example, when
only cytoplasmic, but not membrane Src staining was detected
uniformly throughout a tissue section, the sample was given a
proportion score of 5 for cytoplasm and a proportion score of 0 for
membrane. Similarly when only membrane, but not cytoplasmic
Src staining was detected uniformly throughout a tissue section,
the sample was given a proportion score of 0 for cytoplasm and a
proportion score of 5 for membrane. If both cytoplasm and
membrane were stained at approximately equivalent proportions
(50%) in a tissue section, a proportion score of 3 was given to both
cytoplasm and membrane. The overall Src kinase expression in
each tumor sample was expressed as a histoscore that was the sum
of the proportion score (0–5) and the intensity score (0–3) for a
range of between 0–8, with a maximum possible score of 8
[41].Three different observers M.A., A.A. and B.G.R. were
trained by pathologist KM to score the slides independently and
agreement between the observers was consistent.
Statistical analysis
Values were reported as mean6 SE. The Mann-Whitney U test
was used to analyze the differences in the expression of active and
total Src in cytoplasm and membrane between normal ducts and
cancer tissue, between African American and Caucasian cases,
between low and high proliferative index (Ki67 index), and
between positive and negative lymph node status. The Kruskal-
Wallis H test was used to compare the expression of active and
total Src between grades of carcinoma. The Chi-square test was
used to estimate frequency of expression, activity and subcellular
localization of Src between TNBC and ER+BC. Statistical
analyses were performed using Graph pad Prism 5. A P value
less than 0.05 was considered statistically significant.
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